Osteoporosis International

, Volume 16, Issue 12, pp 2180–2184

Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system

  • C. E. Fiore
  • S. Riccobene
  • R. Mangiafico
  • F. Santoro
  • P. Pennisi
Case Report

Abstract

We report a new case of hepatitis C-associated osteosclerosis (HCAO). The clinical presentation of the patient was an acquired deep severe bone pain with increased serum bone alkaline phosphatase activity (up to 12 times the upper limit of normal), and generalized bone sclerosis, temporally related to the hepatitis C-virus (HCV) infection. We documented in this patient an increase of circulating osteoprotegerin (OPG), and a concentration of circulating receptor activator for nuclear factor-kB ligand (RANKL) below the lower limit of the reference range. The observed abnormalities of the OPG/RANKL system may contribute to the maintenance of the positive balance of bone remodeling that characterizes patients with HCAO.

Keywords

Hepatitis C-associated osteosclerosis OPG RANKL 

References

  1. 1.
    Choo QL, Weiner AJ, Overby LR (1990) Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull 46:423-441PubMedGoogle Scholar
  2. 2.
    Villareal DT, Murphy WA, Teitelbaum SL, Arens MQ, Whyte MP (1992) Painful diffuse osteosclerosis after intravenous drug abuse. Am J Med 93:371–381PubMedGoogle Scholar
  3. 3.
    Beyer HS, Anderson Q, Shih MS, Parfitt AM, Heath H (1993) Diffuse osteosclerosis in intravenous drug abusers. Am J Med 95:660–661CrossRefPubMedGoogle Scholar
  4. 4.
    Whyte MP, Teitelbaum SL, Reinus WR (1996) Doubling skeletal mass during adult life: the syndrome of diffuse osteosclerosis after intravenous drug abuse. J Bone Miner Res 11:554–558PubMedGoogle Scholar
  5. 5.
    Diamond T, Depczysnki B (1996) Acquired osteosclerosis associated with intravenous drug use and hepatitis C infection. Bone 19:679–683CrossRefPubMedGoogle Scholar
  6. 6.
    Whyte MP, Reasner CA (1997) Hepatitis C-associated osteosclerosis after blood transfusion. Am J Med 102:219–229CrossRefPubMedGoogle Scholar
  7. 7.
    Hassoun AAK, Nippoldt TB, Tiegs RD, Khosla S (1997) Hepatitis C-associated osteosclerosis: an unusual syndrome of acquired osteosclerosis in adults. Am J Med 103:70–73Google Scholar
  8. 8.
    Shaker JL, Reims WR, Whyte MP (1998) Hepatitis C-associated osteosclerosis: late onset after blood transfusion in an elderly woman. J Clin Endocrinol Metab 83:93–98CrossRefPubMedGoogle Scholar
  9. 9.
    Wakitani S, Hattori T, Nakaya H, Chae YM, Murata N, Tanigami A (2003) Clinical images: hepatitis C-associated osteosclerosis. Arthritis Rheum 48:268CrossRefPubMedGoogle Scholar
  10. 10.
    Khosla S, Hassoun AAK, Baker BK, Liu F, Zein NN, Whyte MP, Reasner CA, Nippoldt TB, Tiegs RD, Hintz RL (1998) Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. J Clin Invest 101:2165–2173PubMedGoogle Scholar
  11. 11.
    Khosla S, Ballard FJ, Conover CA (2002) Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis. J Clin Endocrinol Metab 87:3867–3870PubMedGoogle Scholar
  12. 12.
    Khosla S (2001) Minireview: the OPG/RANK/RANKL system. Endocrinology 142:5050–5055CrossRefPubMedGoogle Scholar
  13. 13.
    Shaker JL, Moore BP, Whyte MP (1999) Hyperparathyroidism and increased serum IGF-binding protein-2 levels in hepatitis C-associated osteosclerosis. J Clin Endocrinol Metab 84:384–385CrossRefPubMedGoogle Scholar
  14. 14.
    Whyte MP, Chines A, Silva DP, Landt Y, Ladenson JH (1996) Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders. J Bone Miner Res 11:1438–1443PubMedGoogle Scholar
  15. 15.
    Pennisi P, Signorelli SS, Riccobene S, Celotta G, Di Pino L, La Malfa T, Fiore CE (2004) Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int 15:389–395CrossRefPubMedGoogle Scholar
  16. 16.
    Szalay F, Hegedus D, Lakatos PL, Tornai I, Bajnock E, Dunkel K, Lakatos P (2003) High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol 38:395–400PubMedGoogle Scholar
  17. 17.
    Burgess TL, Qian YX, Kaufman S, Ring BD, Van G, Capparelli C (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527–538CrossRefPubMedGoogle Scholar
  18. 18.
    Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059–1066PubMedGoogle Scholar
  19. 19.
    Tappero G, Farina M, Negro F, Anfossi G, Mattiello L, Giuli PD, Colombatto P, Brunetto MR, Angeli A, Bonino F (1997) Intrahepatic expression of c-fos, c-myb and c-myc oncogenes: correlation with virus-induced chronic liver disease and response to interferon. Ital J Gastroenterol Hepatol 29:148–154PubMedGoogle Scholar
  20. 20.
    Sabatakos G, Sims NA, Chen K, Aoki K, Kelz MB, Amling M, Bouali V, Mukhopadhyay K, Ford K, Nestler EJ, Baron R (2000) Overexpression of ΔFos B transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med 6:985–990CrossRefPubMedGoogle Scholar
  21. 21.
    Jochum W, David JP, Elliot C, Wutz A, Plenk H, Matsuo K, Wagner EF (2000) Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med 6:980–984CrossRefPubMedGoogle Scholar
  22. 22.
    Matsuo K, Owens JM, Tonko M, Elliot C, Chambers TJ, Wagner EF (2000) Fos-1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 24:184–187CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2005

Authors and Affiliations

  • C. E. Fiore
    • 1
  • S. Riccobene
    • 1
  • R. Mangiafico
    • 1
  • F. Santoro
    • 1
  • P. Pennisi
    • 1
  1. 1.Department of Internal MedicineUniversity of Catania OVECataniaItaly

Personalised recommendations